☆ 4.7 Editorial Material

Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Volume 308, Issue 15, Pages 1581-1583

Publisher

AMER MEDICAL ASSOC

DOI: 10.1001/jama.2012.14171

Keywords

-

Categories

Medicine, General & Internal

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Cell Biology

Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?

Alexandre A. Jacome, Benny Johnson

Summary: Despite advances in CRC therapy, recurrence rates remain high. Current methods for determining adjuvant chemotherapy eligibility are inaccurate. However, ctDNA detection offers a promising approach for identifying MRD and refining treatment decisions. Ongoing clinical trials and future perspectives hold potential for improved care in both localized and advanced CRC.

CELLS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Microsatellite Instability in Russian Patients with Colorectal Cancer

Vitaly Shubin, Yury Shelygin, Sergey Achkasov, Oleg Sushkov, Ilya Nazarov, Alexey Ponomarenko, Iuliia Alimova, Anna Loginova, Aleksey Tsukanov

Summary: The aim of this study was to determine the characteristics of Russian patients with microsatellite instability (MSI) tumors. The results showed that patients with MSI tumors differed in the age of diagnosis, tumor localization, time of cancer recurrence, and stage of the disease. Patients whose tumors had MSI status had higher overall and disease-free survival rates.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Immunology

Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack

Surendra Raj Sharma, Shahid Karim

Summary: Ticks and tick-borne diseases pose significant public health concerns, with bioactive molecules in tick saliva facilitating the transmission of pathogens such as the alpha-gal antigen. Alpha-gal syndrome (AGS), a newly reported food allergy, is characterized by IgE antibody-directed hypersensitivity against alpha-gal, a sugar molecule found in tick saliva. While the alpha-gal antigen has been identified in various tick species, the immune mechanisms linking tick bites to alpha-gal-specific IgE production remain poorly understood.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Finding the needle in the haystack: the diagnostic accuracy of the faecal immunochemical test for colorectal cancer in younger symptomatic patients

Nigel D'Souza, Kevin Monahan, Sally C. Benton, Lisa Wilde, Muti Abulafi

Summary: Detectable fecal hemoglobin on FIT in symptomatic younger patients may indicate referral for investigation of colorectal cancer and serious bowel disease. The sensitivity of FIT for younger patients aged <50 was 87.5%, 81.3%, and 68.8% at different fecal hemoglobin cut-offs, with a high negative predictive value for colorectal cancer at all cut-offs.

COLORECTAL DISEASE (2021)

Add to Collection

Article Infectious Diseases

Disseminated Tularemia: Finding the Needle in the Haystack

Sean Stringham, Andrea Green Hines, Jonah Attebery, Lisa Darwin, Abby Wachholtz, Ashley Deschamp, Ojasvini Choudhry, Kari Neemann

Summary: This case report presents a case of disseminated tularemia in an 8-month-old male, with atypical symptoms and involvement of multiple organ systems. The diagnosis was confirmed through bronchoalveolar lavage culture, and the patient responded well to treatment with gentamicin. The case highlights the importance of considering tularemia in cases with multisystem organ involvement.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)

Add to Collection

Article Oncology

Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X

Karolin Bucksch, Silke Zachariae, Aysel Ahadova, Stefan Aretz, Reinhard Buttner, Heike Goergens, Elke Holinski-Feder, Robert Hueneburg, Matthias Kloor, Magnus Knebel Doeberitz, Swetlana Ladigan-Badura, Gabriela Moeslein, Monika Morak, Jacob Nattermann, Huu Phuc Nguyen, Claudia Perne, Silke Redler, Ariane Schmetz, Verena Steinke-Lange, Harald Surowy, Deepak B. Vangala, Juergen Weitz, Markus Loeffler, Christoph Engel

Summary: This study aimed to characterize and compare the risks for adenoma and CRC in Lynch syndrome (LS), Lynch-like syndrome (LLS) and familial colorectal cancer type X (FCCX). The study found similar risks for colorectal adenomas, but different risks for first and metachronous CRC between the three risk groups, with CRC risk highest in LS, followed by LLS and lowest in FCCX. Male sex and a prevalent adenoma in the index colonoscopy were associated with a higher risk for incident adenoma and CRC.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

Hereditary Colorectal Cancer: State of the Art in Lynch Syndrome

Antonio Nolano, Alessia Medugno, Silvia Trombetti, Raffaella Liccardo, Marina De Rosa, Paola Izzo, Francesca Duraturo

Summary: Lynch syndrome is a common form of hereditary colorectal cancer associated with variants in Mismatch Repair (MMR) genes. However, many variants identified in these genes remain of uncertain significance. Therefore, individuals with a clinical suspicion of LS often receive a diagnosis of Lynch-like syndrome. This review summarizes the main aspects of Lynch syndrome, recent advances in molecular diagnosis, and the factors that determine the loss of expression of MMR genes.

CANCERS (2023)

Add to Collection

Article Multidisciplinary Sciences

Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer

Abdul Khalid Siraj, Rong Bu, Tariq Masoodi, Sandeep Kumar Parvathareddy, Kaleem Iqbal, Wael Al-Haqawi, Hassan Al-Dossari, Saud Azam, Zeeshan Qadri, Padmanaban Annaiyappanaidu, Fouad Al-Dayel, Khawla Sami Al-Kuraya

Summary: RNF43 mutations are frequently found in Middle Eastern CRC, with a strong association with right-sided and sporadic MSI CRC, and no association with other clinical and pathological features.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Gastroenterology & Hepatology

The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients

Lena Bohaumilitzky, Klaus Kluck, Robert Hueneburg, Richard Gallon, Jacob Nattermann, Martina Kirchner, Glen Kristiansen, Oliver Hommerding, Pauline L. Pfuderer, Lelia Wagner, Fabian Echterdiek, Svenja Koesegi, Nico Mueller, Konstantin Fischer, Nina Nelius, Ben Hartog, Gillian Borthwick, Elena Busch, Georg Martin Haag, Hendrik Blaeker, Gabriela Moeslein, Magnus von Knebel Doeberitz, Toni T. Seppala, Maarit Ahtiainen, Jukka-Pekka Mecklin, D. Timothy Bishop, John Burn, Albrecht Stenzinger, Jan Budczies, Matthias Kloor, Aysel Ahadova

Summary: The immune infiltrate in tumor-distant normal colorectal mucosa from individuals with Lynch syndrome (LS) was assessed. It was found that LS carriers show elevated mucosal T-cell infiltration even in the absence of cancer, and this immune profile may impact tumor risk in LS carriers.

GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Chinese Lynch syndrome-associated colorectal cancer patients' self-concept and adherence to surveillance

Shumin Jia, Xiaodan Wu, Yiheng Zhang, Meifen Zhang

Summary: The study showed that Chinese Lynch syndrome-associated colorectal cancer patients had high adherence to surveillance for colorectal cancer, but lower adherence for extracolorectal cancers. Adherence to surveillance was associated with patients' age and occupation. Chinese patients had slightly higher self-concept scores compared to foreign patients.

EUROPEAN JOURNAL OF CANCER CARE (2021)

Add to Collection

Article Oncology

Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients

Jie-Hai Yu, Bin-Yi Xiao, Jing-Hua Tang, Fang Wang, Ya Ding, Kai Han, Ling-Heng Kong, Yi-Hong Ling, Wei-Jian Mei, Zhi-Gang Hong, Le -En Liao, Wan -Jun Yang, Zhi-Zhong Pan, Xiao-Shi Zhang, Wu Jiang, Pei-Rong Ding

Summary: PD-1 inhibitors are highly effective for dMMR and MSI-H LS CRCs, but not for pMMR or MSS LS CRCs or mucinous/signet-ring cell CRC. Large LS adenomas may also be eliminated by anti-PD-1 treatment.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack

Tamiem Adam, Therese M. Becker, Wei Chua, Victoria Bray, Tara L. Roberts

Summary: In the past decade, significant progress has been made in cancer treatment, with immunotherapy emerging as a new approach. While immunotherapy shows promise in certain cancers, not all patients benefit and may experience serious side effects. The ability to predict who will benefit from immunotherapy is currently limited, but promising biomarkers from tumor tissue, blood, and the microbiome are being explored for personalized treatment strategies.

CANCERS (2021)

Add to Collection

Article Nutrition & Dietetics

A Meta-Analysis of Obesity and Risk of Colorectal Cancer in Patients with Lynch Syndrome: The Impact of Sex and Genetics

Matteo Lazzeroni, Federica Bellerba, Mariarosaria Calvello, Finlay Macrae, Aung Ko Win, Mark Jenkins, Davide Serrano, Monica Marabelli, Sara Cagnacci, Gianluca Tolva, Debora Macis, Sara Raimondi, Luca Mazzarella, Susanna Chiocca, Saverio Caini, Lucio Bertario, Bernardo Bonanni, Sara Gandini

Summary: There is a sex-specific association between obesity and colorectal neoplasia in patients with Lynch Syndrome (LS), with obese men having a twofold risk of CRC compared to nonobese men. The study also found a 49% increased CRC risk for subjects with an MLH1 mutation due to obesity. These results support public measures to reduce overweight in people with LS, particularly for men.

NUTRIENTS (2021)

Add to Collection

Editorial Material Hematology

The CD19neg needle in the haystack

Nirali N. Shah, Terry J. Fry

Summary: In this study, CD34(+)CD19(neg)CD22(+) leukemic progenitor populations were identified, implicating their role in immune escape. These findings shed light on the limitations of single-antigen targeting strategies and our approach to multiantigen targeting, especially in the context of CD19(neg) B-cell acute lymphoblastic leukemia (B-ALL) relapse after CD19 immunotherapy.

BLOOD (2022)

Add to Collection

Article Genetics & Heredity

Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine

Davide Serrano, Paola Patrignani, Vittoria Stigliano, Daniela Turchetti, Stefania Sciallero, Franco Roviello, Alessandro D'Arpino, Ignazio Grattagliano, Salvo Testa, Cristina Oliani, Lucio Bertario, Bernardo Bonanni

Summary: Cancer prevention in the era of precision medicine should consider integrated therapeutic approaches. Low-dose aspirin has been proven to reduce the risk of colorectal cancer in Lynch syndrome carriers and is recommended for CRC prevention.

GENES (2022)

Add to Collection

Article Oncology

Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes

Joseph D. Forrester, Deshka Foster, James M. Ford, Teri A. Longacre, Uri Ladabaum, Sara Fry, Jeffrey A. Norton

Summary: This study reports the long-term outcomes of total gastrectomy for patients with a family history of gastric cancer and CDH1 gene mutations that predispose to hereditary diffuse gastric cancer (HDGC). The results show that total gastrectomy is recommended for patients with inherited CDH1 mutations and the long-term quality of life following the surgery is acceptable.

CANCERS (2022)

Add to Collection

Editorial Material Biochemical Research Methods

MITI minimum information guidelines for highly multiplexed tissue images

Denis Schapiro, Clarence Yapp, Artem Sokolov, Sheila M. Reynolds, Yu-An Chen, Damir Sudar, Yubin Xie, Jeremy Muhlich, Raquel Arias-Camison, Sarah Arena, Adam J. Taylor, Milen Nikolov, Madison Tyler, Jia-Ren Lin, Erik A. Burlingame, Young H. Chang, Samouil L. Farhi, Vesteinn Thorsson, Nithya Venkatamohan, Julia L. Drewes, Dana Pe'er, David A. Gutman, Markus D. Herrmann, Nils Gehlenborg, Peter Bankhead, Joseph T. Roland, John M. Herndon, Michael P. Snyder, Michael Angelo, Garry Nolan, Jason R. Swedlow, Nikolaus Schultz, Daniel T. Merrick, Sarah A. Mazzili, Ethan Cerami, Scott J. Rodig, Sandro Santagata, Peter K. Sorger

Summary: The imminent release of tissue atlases combining multichannel microscopy with single-cell sequencing and other omics data from normal and diseased specimens calls for data and metadata standards to guide data deposition, curation and release. The Minimum Information about Highly Multiplexed Tissue Imaging (MITI) standard, derived from best practices in genomics and microscopy, is introduced for highly multiplexed tissue images and traditional histology.

NATURE METHODS (2022)

Add to Collection

Article Oncology

Somatic tumor testing implications for Lynch syndrome germline genetic testing

Kathleen Barrus, Natasha Purington, Nicolette Chun, Uri Ladabaum, James M. Ford

Summary: In cancer treatment, somatic tumor sequencing is commonly used to tailor therapy, but it can also identify patients with germline pathogenic variants causing cancer predisposition syndromes like Lynch syndrome. However, clinicians seem to be unaware of this implication and fail to refer a significant proportion of these patients for genetic testing.

CANCER GENETICS (2022)

Add to Collection

Editorial Material Oncology

A Novel Framework for the Next Generation of Precision Oncology Targets

Christopher T. Chen, James M. Ford

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial

Stephanie Archer, Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, Rochelle Gold, Alice Fan, Kate Downes, James Ford, Antonis C. Antoniou, Allison W. Kurian, D. Gareth Evans, Marc Tischkowitz

Summary: This study aims to test the effectiveness of personalized risk estimates in supporting women's mental health and choices about their clinical care. It also evaluates the acceptability, feasibility, and cost-effectiveness of using personalized risk estimates in clinical care.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1

Yujeong Lee, Yoshiyuki Onishi, Lisa McPherson, Anna M. Kietrys, Marian Hebenbrock, Yong Woong Jun, Ishani Das, Shanthi Adimoolam, Debin Ji, Michael G. Mohsen, James M. Ford, Eric T. Kool

Summary: Impaired DNA repair activity is associated with increased cancer rates. This study found that certain tyrosine kinase inhibitors, such as nilotinib, can activate the repair enzyme MTH1, which cleanses oxidatively damaged nucleotides. Structural optimization resulted in compounds that strongly activate MTH1 and decrease mutagenic nucleotides in cellular DNA. These findings suggest that MTH1 activators may be a promising strategy to suppress tumorigenesis in individuals with elevated cancer risks.

ACS CHEMICAL BIOLOGY (2022)

Add to Collection

Article Oncology

Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing

Hannah Llorin, Madeline Graf, Nicolette Chun, James Ford

Summary: This study shows that the presence of mutations in moderate risk breast and ovarian cancer genes identified on tumor genomic profiling (TGP) increases eligibility for germline testing, capturing individuals with hereditary cancer syndromes that would not have otherwise been identified.

CANCER GENETICS (2022)

Add to Collection

Article Oncology

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow

Summary: In the past decade, there have been multiple trials to determine the effectiveness of treating cancer based on specific genomic alterations. However, most patients do not respond to single-agent therapies targeting a single alteration, and drug resistance often develops. To address this, the NCI has developed NCI-ComboMATCH, a study to explore genomically-directed combination therapies and overcome drug resistance.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Genetics & Heredity

Clinical implications of conflicting variant interpretations in the cancer genetics clinic

Elyssa Zukin, Julie O. Culver, Yuxi Liu, Yunqi Yang, Charite N. Ricker, Rachel Hodan, Duveen Sturgeon, Kerry Kingham, Nicolette M. Chun, Courtney Rowe-Teeter, Kathryn Singh, Jason A. Zell, Uri Ladabaum, Kevin J. McDonnell, James M. Ford, Giovanni Parmigiani, Danielle Braun, Allison W. Kurian, Stephen B. Gruber, Gregory E. Idos

Summary: The clinical impact of conflicting classifications of genetic variants issued by commercial laboratories was studied. Results from 2000 patients undergoing genetic testing were analyzed, and discrepancies between laboratory-provided classifications and other laboratories were identified. Only 36% of patients with conflicting classifications had a documented discussion by a provider. The study highlights the frequency of interpretation discrepancies and the importance of clinician awareness.

GENETICS IN MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

James J. Harding, Sarina A. Piha-Paul, Ronak H. H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Brana, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Monica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

Summary: In patients with biliary tract cancer, HER2 alterations correlate with poor prognosis. A phase II clinical trial showed that the tyrosine kinase inhibitor neratinib has some efficacy in treating advanced biliary tract cancers with HER2-mutation positive. The objective response rate to neratinib was 16% (95% CI 4.5-36.1%).

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S. Cogan, Vandana G. Abramson, Judy C. Boughey, Carla Falkson, Matthew P. Goetz, James M. Ford, William J. Gradishar, Rachel C. Jankowitz, Virginia G. Kaklamani, P. Kelly Marcom, Andrea L. Richardson, Anna Maria Storniolo, Nadine M. M. Tung, Shaveta Vinayak, Darren R. Hodgson, Zhongwu Lai, Simon Dearden, Bryan T. Hennessy, Erica L. Mayer, Gordon B. Mills, Thomas P. Slavin, Alexander Gutin, Roisin M. Connolly, Melinda L. Telli, Vered Stearns, Jerry S. Lanchbury, Kirsten M. Timms

Summary: This study evaluated whether the genomic instability score (GIS) distributions of BRCA1/2-deficient estrogen receptor-positive breast cancer (ER + BC) and triple-negative breast cancer (TNBC) are similar to that of ovarian cancer. The results showed that the GIS distribution of BRCA1/2-deficient samples was lower in ER + BC compared to ovarian cancer, but there was no significant difference in TNBC. In TNBC patients, the GIS thresholds were validated using clinical response data to platinum therapy.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Meeting Abstract Oncology

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

Kirsten Timms, Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia G. Kaklamani, Vered Stearns, Vandana G. Abramson, Carla Isadora Falkson, Rachel Catherine Jankowitz, P. Kelly Kelly Marcom, Nadine M. Tung, William John Gradishar, James M. Ford, Shaveta Vinayak, Judy Caroline Boughey, Matthew P. Goetz, Anna Maria Storniolo, Roisin M. Connolly, Andrea L. Richardson, Melinda L. Telli

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.

James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, James M. Cleary, David I. Quinn, Irene Brana, Victor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, James M. Ford, Daniel DiPrimeo, Michael F. Berger, Lisa DeFazio Eli, Funda Meric-Bernstam, David B. Solit, Ghassan K. Abou-Alfa

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Personalised risk prediction in hereditary breast and ovarian cancer: A protocol for a multi-centre randomised controlled trial

Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, R. Gold, Alice Fan, Kate Downes, James Ford, Antonis Antoniou, Allison Kurian, Gareth Evans, Marc Tischkowitz, Stephanie Archer

PSYCHO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty

Summary: The study found that Taselisib monotherapy had limited activity in heavily pretreated cancer patients with PIK3CA-mutated tumors. The presence of a PIK3CA mutation alone does not appear to be a sufficient predictor of Taselisib activity.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.